We are live on ! Find out more
HAE icon

Haemonetics
HAE

270 hedge funds and large institutions have $3.83B invested in Haemonetics in 2022 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 84 increasing their positions, 101 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 21

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

13% more capital invested

Capital invested by funds: $3.39B → $3.83B (+$439M)

12% more funds holding

Funds holding: 241 → 270 (+29)

0.5% less ownership

Funds ownership: 101.35% → 100.85% (-0.5%)

9% less call options, than puts

Call options by funds: $4.6M | Put options by funds: $5.08M

17% less repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 101

Holders
270
Holders Change
+29
Holders Change %
+12.03%
% of All Funds
4.65%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
53
Increased
84
Reduced
101
Closed
21
Calls
$4.6M
Puts
$5.08M
Net Calls
-$482K
Net Calls Change
+$1.7M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$29M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.3M
3
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$15.7M
4
Neuberger Berman Group
Neuberger Berman Group
New York
+$12.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.4M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$45.3M
2
RRAM
River Road Asset Management
Kentucky
-$26.9M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$21.8M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$19.5M
5
LCP
LGT Capital Partners
Switzerland
-$15.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$465M +$348K +4,840 +0.1%
BlackRock
2
BlackRock
New York
$410M -$3.24M -45,185 -0.8%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$397M -$19.5M -271,685 -5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$385M +$12.4M +173,113 +3%
Neuberger Berman Group
5
Neuberger Berman Group
New York
$288M +$12.5M +174,545 +5%
State Street
6
State Street
Massachusetts
$126M +$1.99M +27,667 +2%
Franklin Resources
7
Franklin Resources
California
$100M +$3.39M +47,254 +4%
Fisher Asset Management
8
Fisher Asset Management
Washington
$92.4M -$1.6M -22,231 -2%
Schroder Investment Management Group
9
Schroder Investment Management Group
United Kingdom
$72.8M +$15.7M +218,886 +29%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$65.6M +$1.49M +20,740 +2%
RA
11
Royce & Associates
New York
$64.8M +$2.39M +33,223 +4%
LCP
12
LGT Capital Partners
Switzerland
$57.1M -$15.6M -217,160 -22%
Millennium Management
13
Millennium Management
New York
$55M +$29M +404,582 +119%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$53.2M +$2.44M +34,019 +5%
Northern Trust
15
Northern Trust
Illinois
$48.2M -$827K -11,524 -2%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$46.9M +$17.3M +240,357 +61%
BTW
17
Boston Trust Walden
Massachusetts
$46.6M +$1.5M +20,849 +3%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$45.5M +$1.29M +17,929 +3%
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$41.3M +$10.7M +148,642 +36%
Charles Schwab
20
Charles Schwab
California
$37.5M +$368K +5,123 +1%
Ameriprise
21
Ameriprise
Minnesota
$33.6M +$3.96M +55,121 +14%
HA
22
Heartland Advisors
Wisconsin
$30.5M -$862K -12,000 -3%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$30.1M +$6.34M +88,354 +28%
Norges Bank
24
Norges Bank
Norway
$28.9M +$402K +5,605 +1%
Morgan Stanley
25
Morgan Stanley
New York
$26.4M -$923K -12,853 -3%
1
2 3 4 5

HAE Hedge Fund Activity: Q3 2022 in Review

270 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2022, worth a combined $3.83B — up 13% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new HAE positions and 21 closed out — a net gain of 32 holders — while 84 added to existing stakes and 101 trimmed.

The largest buyer was Millennium Management, adding an estimated $29M. The largest seller was Citadel Advisors, cutting an estimated $45.3M.

  • 270 institutional investors held Haemonetics (HAE) as of Q3 2022, up from 241 in Q2 2022.
  • Funds reported $3.83B of Haemonetics stock for Q3 2022, up 13% quarter-over-quarter.
  • 53 funds opened new Haemonetics positions in Q3 2022 and 21 closed out, a net change of +32 holders.
  • The largest Haemonetics buyer in Q3 2022 was Millennium Management, an estimated $29M added.
  • The largest Haemonetics seller in Q3 2022 was Citadel Advisors, an estimated $45.3M sold.

Based on aggregated 13F filings for Q3 2022.